<DOC>
	<DOC>NCT02980263</DOC>
	<brief_summary>The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease</brief_title>
	<detailed_description />
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Key Active Kawasaki disease defined as: fever ≥38.5°C for ≥5 days four out of five of the following criteria: (i) conjunctival injection, (ii) oral mucous membrane changes, (e.g., injected pharynx, or strawberry tongue), (iii) erythema of hands or feet, (iv) polymorphous rash, (v) cervical lymphadenopathy Key Patients fulfilling any of the following criteria are not eligible for inclusion in this study: Previous Kawasaki Disease diagnosis, refractory and/or incomplete Kawasaki disease (for IVIGnaïve patients, Cohort 1) Patients who had fever for longer than a week (for Intravenous Immunoglobulinnaïve patients, Cohort 1), or longer than 14 days (for Intravenous Immunoglobulinrefractory patients, Cohort 2) History of hypersensitivity to any of the study drugs or to drugs or similar chemical classes or excipients (e.g. citric acid and anhydrous sodium chloride disodium edetate dehydrate polysorbate 80; sodium hydroxide; water for injections) Other protocoldefined inclusion/exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kawasaki disease</keyword>
	<keyword>Coronary artery aneurysm</keyword>
	<keyword>mucocutaneous lymph node syndrome</keyword>
	<keyword>lymph node syndrome</keyword>
	<keyword>canakinumab</keyword>
	<keyword>intravenous immunoglobulin naïve (IVIG-naïve)</keyword>
	<keyword>intravenous immunoglobulin refractory (IVIG-refractory)</keyword>
	<keyword>pediatric</keyword>
</DOC>